相似文献
1
Interleukin (IL-6) Immunotherapy.
Cold Spring Harb Perspect Biol. 2018 Aug 1;10(8):a028456. doi: 10.1101/cshperspect.a028456.
2
Therapeutic uses of anti-interleukin-6 receptor antibody.
Int Immunol. 2015 Jan;27(1):21-9. doi: 10.1093/intimm/dxu081. Epub 2014 Aug 20.
3
A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Semin Immunol. 2014 Feb;26(1):88-96. doi: 10.1016/j.smim.2014.01.009. Epub 2014 Mar 1.
4
The biology and medical implications of interleukin-6.
Cancer Immunol Res. 2014 Apr;2(4):288-94. doi: 10.1158/2326-6066.CIR-14-0022.
5
Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.
Int J Biol Sci. 2012;8(9):1227-36. doi: 10.7150/ijbs.4666. Epub 2012 Oct 24.
6
Immunotherapeutic implication of IL-6 blockade.
Immunotherapy. 2012 Jan;4(1):87-105. doi: 10.2217/imt.11.147.
7
[IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions].
Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(6):433-42. doi: 10.2177/jsci.38.433.
8
IL-6 in inflammation, immunity, and disease.
Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295. doi: 10.1101/cshperspect.a016295.
9
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Pharmacol Ther. 2014 Feb;141(2):125-39. doi: 10.1016/j.pharmthera.2013.09.004. Epub 2013 Sep 27.
10
Immunotherapeutic implications of IL-6 blockade for cytokine storm.
Immunotherapy. 2016 Jul;8(8):959-70. doi: 10.2217/imt-2016-0020.
引用本文的文献
1
Cytokine release syndrome in solid tumors.
Cancer. 2025 Sep 1;131(17):e70069. doi: 10.1002/cncr.70069.
2
Predictive levels of vascular endothelial growth factor (VEGF), thymidine kinase 1 (TK1) with interleukin-6 (IL-6), plasma T cells, NK cells as well as B cells in treating diffuse large B-cell lymphoma receiving rituximab.
J Med Biochem. 2025 Jul 4;44(4):784-791. doi: 10.5937/jomb0-54911.
3
Predictive value of clinical indicators in children with community-acquired pneumonia complicated with Kawasaki disease.
J Pediatr (Rio J). 2025 Aug 12;101(5):101424. doi: 10.1016/j.jped.2025.101424.
4
Serum cytokine profiles in patients with myasthenia gravis.
Front Neurol. 2025 Jul 3;16:1611673. doi: 10.3389/fneur.2025.1611673. eCollection 2025.
5
Purification, Structural Characterization, and Immunomodulatory Activity of an Exopolysaccharide from BJ01 in Fermentation Grains.
Foods. 2025 Jun 20;14(13):2162. doi: 10.3390/foods14132162.
6
Non-invasive hemodynamic monitoring and cardiac preload assessment in severely injured children in the emergency department.
BMC Emerg Med. 2025 Jul 1;25(1):108. doi: 10.1186/s12873-025-01264-2.
7
The Therapeutic Potential of Bombyx Batryticatus for Chronic Atrophic Gastritis Precancerous Lesions via the PI3K/AKT/mTOR Pathway Based on Network Pharmacology of Blood-Entering Components.
Pharmaceuticals (Basel). 2025 May 25;18(6):791. doi: 10.3390/ph18060791.
8
Case Report: Serum sickness induced by dupilumab-clinical insights and Olinkproteomic analysis.
Front Immunol. 2025 Jun 10;16:1512482. doi: 10.3389/fimmu.2025.1512482. eCollection 2025.
9
and activity of sodium houttuyfonate and sodium new houttuyfonate against infection by affecting adhesion, aggregation, and biofilm formation abilities.
Microbiol Spectr. 2025 Jun 18:e0022225. doi: 10.1128/spectrum.00222-25.
10
Synergistic potential of bone marrow mesenchymal stem cells and miR181-a combinational therapy against multiple sclerosis.
Stem Cell Res Ther. 2025 Jun 9;16(1):300. doi: 10.1186/s13287-025-04401-7.
本文引用的文献
1
Immunotherapeutic implications of IL-6 blockade for cytokine storm.
Immunotherapy. 2016 Jul;8(8):959-70. doi: 10.2217/imt-2016-0020.
2
Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.
Eur Heart J. 2016 Aug 7;37(30):2406-13. doi: 10.1093/eurheartj/ehw171. Epub 2016 May 8.
3
Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.
Arthritis Rheumatol. 2016 Oct;68(10):2550-4. doi: 10.1002/art.39740.
4
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Lancet. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4. Epub 2016 May 5.
5
CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer.
Immunity. 2016 Apr 19;44(4):913-923. doi: 10.1016/j.immuni.2016.04.003.
6
CD5: A New Partner for IL-6.
Immunity. 2016 Apr 19;44(4):720-2. doi: 10.1016/j.immuni.2016.03.011.
7
Arid5a regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA.
J Exp Med. 2016 Apr 4;213(4):605-19. doi: 10.1084/jem.20151289. Epub 2016 Mar 28.
8
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Lancet. 2016 May 7;387(10031):1921-7. doi: 10.1016/S0140-6736(16)00560-2. Epub 2016 Mar 4.
9
Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study.
Ann Rheum Dis. 2016 Aug;75(8):1506-10. doi: 10.1136/annrheumdis-2015-208742. Epub 2016 Feb 29.
10
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Arthritis Rheumatol. 2016 Jan;68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6.
Zotero 插件